Long-term Outcome in 7 Patients With Idiopathic Orbital Myositis.

Japanese clinical medicine Pub Date : 2019-08-12 eCollection Date: 2019-01-01 DOI:10.1177/1179670719866525
Toshihiko Matsuo
{"title":"Long-term Outcome in 7 Patients With Idiopathic Orbital Myositis.","authors":"Toshihiko Matsuo","doi":"10.1177/1179670719866525","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Idiopathic orbital myositis, a rare disease of unknown cause, presents a diagnostic puzzle because the diagnosis is based on the exclusion of other diseases. This study aims at elucidating its long-term outcome to answer a clinical question whether idiopathic orbital myositis would be a distinct clinical entity.</p><p><strong>Methods: </strong>Retrospective review was made on 7 consecutive patients (6 men and 1 woman) with the age at the initial visit ranging from 33 to 69 years (mean, 45.8 years) who were diagnosed with idiopathic orbital myositis and followed for 5 years or more (mean, 9.2 years) at a referral-based hospital.</p><p><strong>Results: </strong>Chief complaint at the initial visit was diplopia in 4 patients, blurred vision in 2 patients, and proptosis in 1 patient. On magnetic resonance imaging, 4 patients showed enlargement of a single extraocular muscle on unilateral side while 3 patients showed enlargement of multiple extraocular muscles on unilateral side or bilateral sides. No patient developed systemic diseases or other orbital lesions in the long-term follow-up. All patients at the last visit were free from symptoms, including diplopia, after tapering of prednisolone at the initial dose of 20 to 60 mg daily.</p><p><strong>Conclusion: </strong>Idiopathic orbital myositis had a favorable long-term outcome with corticosteroid administration and appears to be a distinct clinical entity without systemic involvement.</p>","PeriodicalId":89792,"journal":{"name":"Japanese clinical medicine","volume":"10 1","pages":"1179670719866525"},"PeriodicalIF":0.0000,"publicationDate":"2019-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109134/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese clinical medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1179670719866525","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Idiopathic orbital myositis, a rare disease of unknown cause, presents a diagnostic puzzle because the diagnosis is based on the exclusion of other diseases. This study aims at elucidating its long-term outcome to answer a clinical question whether idiopathic orbital myositis would be a distinct clinical entity.

Methods: Retrospective review was made on 7 consecutive patients (6 men and 1 woman) with the age at the initial visit ranging from 33 to 69 years (mean, 45.8 years) who were diagnosed with idiopathic orbital myositis and followed for 5 years or more (mean, 9.2 years) at a referral-based hospital.

Results: Chief complaint at the initial visit was diplopia in 4 patients, blurred vision in 2 patients, and proptosis in 1 patient. On magnetic resonance imaging, 4 patients showed enlargement of a single extraocular muscle on unilateral side while 3 patients showed enlargement of multiple extraocular muscles on unilateral side or bilateral sides. No patient developed systemic diseases or other orbital lesions in the long-term follow-up. All patients at the last visit were free from symptoms, including diplopia, after tapering of prednisolone at the initial dose of 20 to 60 mg daily.

Conclusion: Idiopathic orbital myositis had a favorable long-term outcome with corticosteroid administration and appears to be a distinct clinical entity without systemic involvement.

Abstract Image

Abstract Image

特发性眼眶肌炎7例远期疗效分析
目的:特发性眼窝肌炎是一种罕见的原因不明的疾病,由于其诊断是建立在排除其他疾病的基础上的,因此是一个诊断难题。本研究旨在阐明其长期结果,以回答一个临床问题,特发性眼眶肌炎是否会是一个独特的临床实体。方法:回顾性分析7例(6男1女)首次就诊时年龄33 ~ 69岁(平均45.8岁),在转诊医院随访5年以上(平均9.2年)的特发性眼眶肌炎患者。结果:初诊主诉复视4例,视力模糊2例,眼球突出1例。磁共振成像显示单侧眼外肌增大4例,单侧或双侧多块眼外肌增大3例。在长期随访中,无患者出现全身性疾病或其他眼眶病变。在强的松龙初始剂量为20 - 60mg /天后,所有患者在最后一次访问时均无症状,包括复视。结论:特发性眼窝肌炎在皮质类固醇治疗下具有良好的长期预后,并且似乎是一种独特的临床实体,没有全身受累。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书